Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154240 | 0.91 | S1PR1 (0.41) | PRCPPNMTHTR2CHTR2BHTR2A | |
| SCHEMBL17155489 | 0.86 | PRCP (0.49) | PRCPPNMTHTR2CHTR2BADRA2A | |
| SCHEMBL16154968 | 0.78 | PNMT (0.51) | PRCPPNMTHTR2CHTR2BADRA2A | |
| SCHEMBL17155199 | 0.77 | PNMT (0.43) | PRCPPNMTHTR2CHTR2BHTR2A | |
| SCHEMBL16518130 | 0.75 | PNMT (0.53) | PRCPPNMTHTR2CHTR2BADRA2A | |
| SCHEMBL17154228 | 0.75 | CD44 (0.45) | PRCPPNMTHTR2CHTR2BS1PR1 | |
| SCHEMBL17154231 | 0.71 | HTR2C (0.51) | HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL11493075 | 0.71 | PRCP (0.71) | PRCPPNMTADRA2AADRA2BADRA2C | |
| SCHEMBL14677593 | 0.70 | PNMT (0.72) | PRCPPNMTHTR2CADRA2AADRA2B | |
| SCHEMBL16154954 | 0.70 | PRCP (0.60) | PRCPPNMTHTR2CADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388179-B2 | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN1B, SCN1A, SCN2B | PRCP 4795/4885PNMT 3290/4885HTR2C 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.